[1]
Gentile I, Scotto R, Zappulo E, et al. Investigational direct-acting antivirals in hepatitis C treatment: The latest drugs in clinical development. Expert Opin Investig Drugs 2016; 25: 557-72.
[2]
Westerhoff M, Ahn J. Chronic Hepatitis C and direct acting antivirals. Surg Pathol Clin 2018; 11: 287-96.
[3]
Gentile I, Buonomo AR, Borgia G. Ombitasvir: A potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014; 12: 1033-43.
[4]
Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl. 1): 93-104.
[5]
Gentile I, Borgia F, Buonomo AR, et al. ABT-450: A novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2014; 21: 3261-70.
[6]
Gentile I, Buonomo AR, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag 2014; 10: 493-504.
[7]
Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20: 9633-52.
[8]
Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol 2018; 41: 26-9.
[9]
Chhatwal J, Wang X, Ayer T, et al. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (Baltimore, Md) 2016; 64: 1442-50.
[10]
Lanini S, Easterbrook PJ, Zumla A, et al. Hepatitis C: Global epidemiology and strategies for control. Clin Microbiol Infect 2016; 22: 833-8.
[11]
Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014; 23: 1211-23.
[12]
Gentile I, Borgia G. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. Evid Based Med 2014; 19: 223-4.
[13]
Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-65.e1.
[14]
Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68(4): 663-71.
[15]
Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther 2017; 46: 540-8.
[16]
Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int 2019; 13: 66-7.
[17]
Mensa FJ, Lovell S, Pilot-Matias T, et al. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019; 14: 89-110.
[18]
Hubbard H, Lawitz E. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. Expert Rev Gastroenterol Hepatol 2018; 12: 9-17.
[19]
Bourliere M, Pietri O, Castellani P, et al. Sofosbuvir, velpatasvir and voxilaprevir: A new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018; 11: 1756284818812358.
[20]
Voaklander R, Jacobson IM. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol 2017; 11: 789-95.
[21]
Borgia G, Maraolo AE, Buonomo AR, et al. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs 2016; 25: 1209-14.
[22]
Greig SL. Sofosbuvir/Velpatasvir: A review in chronic Hepatitis C. Drugs 2016; 76: 1567-78.
[25]
Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373: 2599-607.
[26]
Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373: 2608-17.
[27]
Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-28.
[28]
Stamm LM, Brainard DM, McHutchison JG. Sofosbuvir/ velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018. J Hepatol 2019; 70(3): 561-2.
[29]
European Association for the Study of the Liver Reply to: “Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018”: EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the treatment of patients with genotype 3a infection and compensated cirrhosis. J Hepatol 2019; 70(3): 562-4.
[30]
Landis CS, Sulkowski MS, Reau N, et al. Safety and efficacy of velpatasvir and sofosbuvir-based regimens for the treatment of HCV genotype 1–6: Results of the HCV-TARGET study. Hepatology 2017; 66: 587A.
[31]
Buggisch P, Atanasov P, Wursthorn K, et al. Real-world effectiveness and cost per svr of sofosbuvir/velpatasvir chronic Hepatitis C treatment. Hepatology (Baltimore, Md) 2017; 66: 856A.
[32]
Boyle A, Marra F, Peters E, et al. PS-034 - 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort. J Hepatol 2018; 68: S20.
[33]
Ferret MB, Pineda J, Panero JLC, et al. PS-035 - Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis. J Hepatol 2018; 68: S20-1.
[34]
Nguyen E, Trinh S, Trinh H, et al. THU-346 - Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir. J Hepatol 2018; 68: S284-5.
[35]
Hu C, Yuan G, Liu J, et al. Sofosbuvir-based therapies for patients with Hepatitis C virus infection: Real-world experience in China. Can J Gastroenterol Hepatol 2018; 2018: 3908767.
[36]
Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol 2019; 70: 15-23.
[37]
Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17: 1062-8.
[38]
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with Hepatitis C Virus and human immunodeficiency virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis 2018; 67: 1010-7.
[39]
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378: 354-69.
[40]
Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/pibrentasvir for 8 or 12 weeks in patients with Hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018; 16: 417-26.
[41]
Foster GR, Gane E, Asatryan A, et al. GS-007 - ENDURANCE-3: Safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis. J Hepatol 2017; 66: S33.
[42]
Flamm SL, Kort J, Marx S, et al. Effectiveness of 8‐Week Glecaprevir/Pibrentasvir (G/P) for treatment naïve, non‐cirrhotic patients with HCV infection in the trio health network. Hepatology 2017; 1: 1.
[43]
Berg T, Naumann U, Stoehr A, et al. GS-007 - First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry. J Hepatol 2018; 68: S37.
[44]
Belperio PS, Shahoumian T, Loomis T, et al. Real‐world effectiveness of Glecaprevir/Pibrentasvir in 1,941 patients with Hepatitis C genotypes 1 through 4. Hepatology 2017; 66: 1.
[45]
D’Ambrosio R, Pasulo L, Puoti M, et al. Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 2018; 68(Suppl. 1): S65.
[46]
Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 2019; 54(3): 291-6.
[47]
Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. J Med Virol 2019; 91: 102-6.
[48]
Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 2017; 153: 113-22.
[49]
Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV Infection. N Engl J Med 2017; 376: 2134-46.
[50]
Pearlman BL, Hinds A, Perrys M. Sofosbuvir/Velpatasvir/ Voxilaprevir (SOF/VEL/VOX) for prior treatment failures with Glecaprevir/Pibrentasvir (G/P) in chronic Hepatitis C infection. Hepatology 2017; 66: 1.
[51]
Hezode C, Guyader D, Nguyen-Khac E, et al. Sofosbuvir + Velpatasvir + Voxilaprevir in Daa failure patients with cirrhosis. Final Results of the French Compassionate Use Program. Hepatology 2017; 66.
[52]
Vermehren J, Dietz J, Pieffer KH, et al. Resistance analysis in direct acting antiviral‐experienced patients with chronic Hepatitis C virus infection treated with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) ‐ results from the frankfurt resistance database. Hepatology 2017; 66.
[53]
Bacon BR, Curry MP, Flamm SL, et al. Sofosbuvir/Velpatasvir/ Voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis c patients; Clinical practice experience from the trio network. Hepatology 2017; 66.
[54]
Gentile I, Maraolo AE, Buonomo AR, et al. The discovery of sofosbuvir: A revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov 2015; 10: 1363-77.
[55]
Lim TS, Ahn SH. Use of sofosbuvir in chronic kidney disease: Is it necessary? Clin Mol Hepatol 2017; 23: 308-10.
[56]
Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic Hepatitis C: the dawn of the a new era. Rev Recent Clin Trials 2014; 9: 1-7.
[57]
Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat 2017; 24: 442-53.
55
4